 |
|
|
| |
POORER NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART
ACTG HIV Reservoirs Cohort study A5321
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Kevin Robertson1, Ronald Bosch2, Serena S. Spudich3, Rajesh T. Gandhi4, Joshua C. Cyktor5, Hanna Mar2, Bernard J. Macatangay5, Christina Lalama2,
Charles Rinaldo5, Ann Collier6, Catherine Godfrey7, Joseph J. Eron1, Deborah McMahon5, John W. Mellors5for the A5321 Team.
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Harvard University, Boston, MA, USA, 3Yale University, New Haven, CT, USA,
4Brigham and Women's Hospital, Boston, MA, USA, 5University of Pittsburgh, Pittsburgh, PA, USA, 6University of Washington, Seattle, WA, USA, 7NIH, Bethesda, MD, USA.
from Jules: again: if ATI or stopping ART increases HIV in the CSF and the brain, which was reported in the monkey study at CROI which I just reported, and it has been reported previously that stopping ART can increase HIV CNS viral escape, then Serene Spudich’s study I just reported from CROI where she finds HIV CSF persists despite suppressive ART,then this study by Robertson finds worse cognitive performance with CSF HIV DNA on long term ART - it stands to reason that perhaps stopping ART increases risk for increasing HIV in CSF & the brain which if true could lead to cognitive & neurologic impairment not just in short term but down the road long term. These are reasonable assumptions yet have not been adequately addressed years after conducting ATIs in cure studies.
|
| |
|
|
|
|
|
